United Therapeutics Corp. (NASDAQ:UTHR) said it sold a rare pediatric disease Priority Review voucher to AbbVie Inc. (NYSE:ABBV) for $350 million. AbbVie spokesperson Adelle Infante declined to disclose the company's
Read the full 308 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury